

Award Number:

W81XWH-13-2-0017

TITLE:

Development of in vivo Biomarkers for Progressive Tau Pathology after
Traumatic Brain Injury

PRINCIPAL INVESTIGATORS:

Marc Diamond, M.D.

CONTRACTING ORGANIZATION:

Washington University, St Louis MO 63110

REPORT DATE:

February 2014

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) February 2014		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15January2013-14January2014	
4. TITLE AND SUBTITLE Development of in vivo Biomarkers for Progressive Tau Pathology after Traumatic Brain Injury			5a. CONTRACT NUMBER W81XWH-13-2-0017		
			5b. GRANT NUMBER W81XWH-13-2-0017		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Marc I Diamond			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University 660 S Euclid Ave St Louis, MO 63110			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Athletes in contact sports who have sustained multiple concussive traumatic brain injuries are at high risk for delayed, progressive neurological and psychiatric deterioration ¹⁻⁹ . This syndrome is termed chronic traumatic encephalopathy (CTE) ^{1,7,10} , and is also known as dementia pugilistica ^{3,11} or 'punch drunk' syndrome ^{9,12} . US military personnel ^{13,14} and others who have sustained multiple concussive traumatic brain injuries ¹⁵⁻¹⁷ may also be at risk for this condition. Currently, there are no methods to identify progressive tau pathology in living humans. Hypothesis: Aggregated forms of hyperphosphorylated tau protein formed acutely in the setting of traumatic brain injury can seed further aggregation of intracellular tau in nearby cells, leading to delayed propagation of tau pathology and neurodegeneration. Objective: To develop standardized, high-throughput blood and cerebrospinal fluid assays for aggregated forms of tau responsible for propagation of tau pathology after traumatic brain injury. Progress to date: The major year 1 goal for the Brody lab was to determine which mouse model of experimental TBI and which human tau transgenic mouse line would be most useful for these experiments. We have determined that controlled cortical impact in 3xTg-AD mice will be optimal. The major year 1 goal for the Diamond lab was to refine and standardize the tau propagation assay. We have increased the sensitivity of the assay by nearly 1000 fold using a flow-cytometry based assay and established quantitative standard curves.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES 12	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusion.....	10
References.....	11
Appendices.....	12

INTRODUCTION:

Athletes in contact sports who have sustained multiple concussive traumatic brain injuries are at high risk for delayed, progressive neurological and psychiatric deterioration¹⁻⁹. This syndrome is termed chronic traumatic encephalopathy (CTE)^{1, 7, 10}, and is also known as dementia pugilistica^{3, 11} or 'punch drunk' syndrome^{9, 12}. US military personnel^{13, 14} and others who have sustained multiple concussive traumatic brain injuries¹⁵⁻¹⁷ may also be at risk for this condition. Hyperphosphorylation and aggregation of tau protein are key pathological features of chronic traumatic encephalopathy, but at present they can only be observed post-mortem^{1, 3, 6, 18-20}. Tau pathology has also been observed after single more severe traumatic brain injuries²¹⁻²³. Currently, there are no methods to identify progressive tau pathology in living humans. The progressive aspect of chronic traumatic encephalopathy suggests that repetitive injuries may trigger an ongoing degenerative process similar to other diseases characterized by progressive tau pathology such as Alzheimer disease and frontotemporal dementia. A leading hypothesis regarding the progression of tau pathology in Alzheimer disease and frontotemporal dementia is that tau aggregates formed in one cell can propagate by exiting that cell and entering anatomically connected cells to induce tau aggregation in these cells²⁴⁻³⁰. While the tau pathology in chronic traumatic encephalopathy is distinct from other diseases, the propagation model offers a new conceptual framework to test these ideas in chronic traumatic encephalopathy.

The development of diagnostic tests and approaches to monitor the progression of post-traumatic tau pathology has been limited both by the lack of an appropriate small animal model and the lack of a suitable assay system. The Brody lab has recently developed a small animal model. Specifically, controlled cortical impact traumatic brain injury in 3xTg-AD and TauP301L mice, two transgenic mouse lines overexpressing mutant forms of human tau, caused tau aggregation and hyperphosphorylation in the fimbria, amygdala and hippocampi³¹⁻³³. In parallel, the Diamond lab has recently developed cultured cell-based assays that can be used to monitor tau aggregation and trans-cellular propagation of aggregation. These assays can detect the effects of extracellular tau aggregates that cause fibril formation of native intracellular tau in cultured cells (i.e. 'seeding'), and can also track the movement of aggregates between cells^{25, 26}. These advances now create an opportunity to test key hypotheses about the pathogenesis of chronic traumatic encephalopathy for the first time. In turn, a detailed understanding of this pathogenesis in experimental settings may lead to the rational development of conceptually novel diagnostic tests and therapeutic approaches in humans.

Hypothesis: Aggregated forms of hyperphosphorylated tau protein formed acutely in the setting of traumatic brain injury can seed further aggregation of intracellular tau in nearby cells, leading to delayed propagation of tau pathology and neurodegeneration.

Objective: To develop standardized, high-throughput blood and cerebrospinal fluid assays for aggregated forms of tau responsible for propagation of tau pathology after traumatic brain injury.

Specific Aims

TASK 1: *To assess extracts from the brains of tau transgenic mice subjected to experimental traumatic brain injury for tau aggregating activity using a cultured-cell based assay.*

TASK 2: *To determine whether mouse blood and cerebrospinal fluid tau aggregating activity quantitatively predict brain tau pathology and neurodegeneration in mice subjected to experimental traumatic brain injury*

TASK 3: *To test whether antibodies that block tau aggregating activity in cultured cell-based assays also block tau pathology, neurodegeneration and behavioral deficits in mice subjected to experimental traumatic brain injury*

TASK 4: *To develop an antibody-based assay for tau aggregating activity.*

Tasks 1 and 4 are largely performed by the Diamond lab.

BODY:

We have made progress on Tasks 1 and 4.

To summarize progress on Task 1, we have found that repetitive concussive TBI does not appear to reliably accelerate tau pathology in young transgenic mice, whereas controlled cortical impact TBI causes a transient but not progressive increase in tau pathology. The Diamond lab has contributed to all aspects of assay development.

Specifically, we have performed the following experiments and found the following results:

- 1) Controlled cortical impact TBI in 6 month old 3xTg-AD mice causes an increase in tau immunoreactivity at 1 day and 7 days after injury, but 6 months after injury this tau pathology is largely resolved. At 1 day and 7 days, the pathology is apparent in ipsilateral fimbria, ipsilateral amygdala, and contralateral hippocampus.
- 2) Repetitive concussive (2x- 24 hours apart) TBI in 6-8 week old hTau mice does not cause any increase in tau immunoreactivity detectible at 7 days or 6 weeks after injury. None of the mice at these ages have any abnormal tau immunoreactivity.
- 3) Repetitive concussive (4x injury, 24 hours apart) TBI in 6-8 week old hTau mice did not cause any increase in tau immunoreactivity detectible 6 months after injury. Both groups had quantitatively similar CP13 anti-tau immunoreactivity in subgranular layers of dentate gyrus, as assessed using blinded unbiased stereology (Figure 1). Figure 1




Figure 1

This 4x injury paradigm caused substantial axonal injury, as evidenced by silver staining in the ipsilateral corpus callosum and external capsule (Figure 2). However, the extent of silver staining did not differ as a function of genotype: hTau mice expressing full length human tau had no difference from tau knockout mice in blinded quantitative densitometry assessments.





Figure 2

- 4) Repetitive concussive (4x injury, 24 hours apart) TBI in 6-8 week old tau P301S mice does not cause any increase in tau immunoreactivity detectable at 7 days or 6 weeks after injury. Litter-to-litter variability in the extent of tau immunoreactivity make quantitative assessments in this line of mice challenging.

As part of the development of Aim 1, we have put new effort into refining our ability to detect tau seeding activity. This is because we realized that the plate reader-based assay we were using had important limitations, both in sensitivity, and in its use to characterize many samples sensitively and precisely. The new assay was based on development of the original, but with important improvements. The assay uses a fragment of the tau protein consisting of the “repeat domain” (RD) containing a single, disease-associated mutation (P301S). This mutation predisposes the tau protein to readily aggregate. When fused to cyan and yellow fluorescent proteins (tau-CFP or tau-YFP) this tau protein serves as a “biosensor” that, when expressed in cells, enables a response to tau seeds on the cell exterior. These extracellular seeds are transported into the cell via macropinocytosis, where they trigger aggregation of tau-CFP/YFP. This aggregation event is likely to be catastrophic within the cell, meaning that once a cell converts, virtually all of the tau forms aggregates (Figure 3). This work has been performed by the Diamond lab.

Figure 3: Tau constructs and methods of analysis. (A) Schematic of constructs used. Full-length tau and the repeat domain (RD) region. RD fusions to CFP and YFP allow quantification of intracellular aggregation using FRET between CFP and YFP. (B) Recombinant RD and full-length tau fibrils are labeled with AlexaFluor to quantify cell uptake and binding using flow cytometry or high content microscopy. (C) Recombinant fibrils added to cells expressing tau RD-CFP/YFP induce aggregation that is measured by FRET. (D) Flowchart of biosensor system to detect proteopathic “seeds.”



Previously, we monitored this process using a fluorescence plate reader. In this case, the aggregation events were read out as an average across the entire well in 96-well plate. We created two innovations to improve this system. First, we created stable cell lines expressing tau-CFP/YFP. We selected our biosensor cell line to eliminate any background aggregation. Second, instead of using a plate reader, we adapted a flow cytometer to monitor protein aggregation within single cells. This dramatically increased the sensitivity and dynamic range of our assay, since we were able

to detect single cell conversion events within a population of ~120,000 cells. The increase in sensitivity vs. the plate reader system is approximately 10,000x, and the dynamic range increase is approximately 100x (Figure 4). This work was from the Diamond lab.

Figure 4: Detection of specific tau seeding activity.

(A) Stable HEK/tau-CFP/YFP reporter cells were grown in a 96-well plate and exposed to the indicated range of tau fibrils. 48h later cells were fixed and FRET levels determined by FPR. Significant induction of FRET signal occurred at 5nM fibrils. (B) Stable HEK/tau-CFP/YFP reporter cells were exposed to a range of recombinant RD tau fibrils, followed by flow cytometry to monitor induced FRET. There was a ~1000-fold increase in the number of FRET-positive cells over the range of concentrations. The lowest concentration reliably detected ($p<.05$) was 300fM tau. At 10pM, the Z' value of the assay was $>.5$. Integrated FRET Density refers to the average FRET signal from each individual cell x the number of positive cells, relative to baseline signal. Error bars=SEM. As part of the analysis of this assay, we have used it to analyze the brains of P301S transgenic tauopathy mice, which develop gradually progressive pathology over many months. These mice have been extensively characterized in our group for other purposes (REF: Yanamandra et al. Neuron 2013). We know that they develop evidence of neurofibrillary tau pathology between the ages of 4-5mos. This is associated with biochemical evidence of tau accumulation around 9mos, when detergent-insoluble protein becomes detectable. We used the seeding assay to characterize these animals, testing whether the biosensor system could robustly anticipate the development of *bona fide* neuropathology. We sacrificed P301S mice at various ages, and analyzed brain homogenates for the presence of tau pathology. With the new seeding assay, we observed clear evidence of tau pathology at ~6weeks of ages, well before the development of classical neuropathology (Figure 5). This work was performed in the Diamond lab.





Figure 5: Seeding activity from cortex over time. P301S mice were killed at different ages as indicated, and the seeding activity was quantified in the cortex, using the HEK/tau-CFP/YFP biosensor cell line. Consistent seeding activity was detected at age 6 weeks ($p<.0001$) in P301S mice. Brains from WT mice age 2-24 weeks had no significant activity (right-most points). The dotted vertical line indicates the approximate point at which tau tangles are detected by standard histopathology. Fibrils (Fib) are used as a positive control (left-most points). Note the log scale on the Y axis, indicating the enormous range of seeding activity present over time in P301S mice. The Diamond lab has refined the tau aggregation assays substantially since the time of the initial application. This has resulted in reliable and quantitative standard curves using recombinant 4 repeat domain (4RD) tau fibrils. In the refined flow-cytometry-based assays, tau aggregation induced in transfected HEK293 cells is expressed as integrated FRET (Fluorescence Resonance Energy Transfer) intensity.



However, even using the refined, quantitatively precise assays, we have not observed any reproducible induction of tau aggregating activity by experimental TBI. Specifically, we have found the following:

- 1) Controlled cortical impact TBI in 6 month old 3xTg-AD mice did not cause any increase in tau aggregation at either 1 day or 7 days after injury compared to sham 3xTg-AD mice.
- 2) Repetitive concussive (2x injury, 24 hours apart) TBI in 6-8 week old hTau mice did not reliably increase tau aggregation activity in hippocampal or cortical lysates. When we repeated assessments of the hippocampal lysates presented in Table 1 of progress report #1 using the more sensitive assay, we found no significant increase in tau aggregation activity in the injured mice.
- 3) Repetitive concussive (4x injury, 24 hours apart) TBI in 6-8 week old tau P301S mice does not cause any increase in tau aggregation in either hippocampal lysates, cortical lysates, blood or cerebrospinal fluid 7 days after injury. In one experiment, there was a trend towards reduced tau aggregation in the injured mice compared with the

sham mice in hippocampal and cortical lysates (Figure 6).

Tau Seeding in P301S mice 7d after 4xrcTBI




Figure 6

- 4) Repetitive concussive (4x injury, 24 hours apart) TBI in 6-8 week old tau P301S mice does not cause any increase in tau aggregation in either hippocampal lysates, cortical lysates, blood or cerebrospinal fluid 3 months after injury (Figure 7)

Seeding from 3 mo. P301S mice - Injured vs. Uninjured





Figure 7

We have been developing a bead-based detection method to monitor the development of tau aggregation. This exploits the flow cytometer to monitor the production of aggregates trapped on nano-particles that flow past a detector. In brief, a nanoparticle of approximately 100nm diameter is coated with a single anti-tau monoclonal antibody. This bead is then exposed to material containing tau aggregates. A detection antibody containing the identical antibody labeled with a fluorescent dye (e.g. Alexa488) is incubated with the sample. The bead:Ag:Ab complex is detected by flow cytometry. Preliminary evidence indicates that this “sandwich” detection method provides robust discrimination between populations of recombinant monomer vs. fibrils (Figure 8). We have not yet determined the sensitivity of this assay, nor have we used it yet in mouse models of tauopathy. This work is from the Diamond lab.

Figure 8: In vitro detection of tau aggregates. Nanoparticles are coated with anti-tau monoclonal antibody (HJ9.3) that was exposed to tau monomer (A) or tau fibrils (B). Particles were then exposed to the same antibody linked to a fluorescent dye (Alexa488), washed and fluorescence intensity per bead was assessed by flow cytometry. (C) Cytometry shows a clear discrimination of beads exposed to monomer vs. fibrils. This indicates that it may be possible to use bead-based flow cytometry systems to monitor tau aggregate production.



Summary: Thus, the major finding from the first year of the project is that in all mice tested to date, tau pathology induced by TBI is a transient phenomenon that does not appear to propagate or increase over time. This raises a major question: What are the mechanisms underlying clearance of tau pathology in these young mice? It is possible that any tau pathology arising in the repetitive concussive models could have been rapidly cleared and therefore not detected by our immunohistochemical methods.

Our plan for the next project period is to investigate the mechanisms underlying tau clearance using the most promising mouse model: 3xTg-AD mice injured using controlled cortical impact. Hypotheses to be tested include that dephosphorylation by protein phosphatases leads to disaggregation of tau, ubiquitination leads to degradation of tau, and inductions of autophagy leads to lysosomal degradation of tau aggregates.³⁴ It may be that tau is cleared more aggressively in the brains of mice than in the brains of humans. If so, inhibition of one or more of the endogenous tau clearance mechanisms will be required to recapitulate progressive tau pathology in a mouse model following TBI to accurately recapitulate the human phenotype.

In all animals, clearance of protein aggregates declines with age. Therefore, in parallel, we will test the hypothesis that repetitive concussive injuries in older mice (6-12 months) may cause progressive tau pathology. Towards this end, we have begun characterizing a 5x repetitive closed skull injury model using a midline 1 mm metal tip impact as developed by the Crawford lab³⁵. Our current repetitive concussive injury model involves a 3.3 mm rubber tip impact which does not cause concussive TBI in mice older than 8 weeks of age (TJ Esparza, RE Bennett, DL Brody, unpublished data) due presumably to their thicker skulls.

A second major finding from the first year of the project is that tau aggregation activity measured by FRET may not necessarily always reflect TBI-related tau pathology. Accordingly, we plan to extend our search for a blood or CSF-based marker for tau pathology using mass-spectrometry based discovery of tau post-translational modifications. If successful, one or more characteristic tau post-translational modifications could be targeted for an ELISA-type assay which would be appropriate for widespread use.

KEY RESEARCH ACCOMPLISHMENTS:

- 1) Controlled cortical impact injury in 6 month old 3xTg-AD mice cause a transient but not progressive increase in tau pathology. However, repetitive concussive injury in 6-8 week old hTau and P301S did not.
- 2) Sensitivity of tau aggregation assays has improved substantially. However, the tau aggregation assays have not correlated fully with tauopathy.

REPORTABLE OUTCOMES:

None

CONCLUSION:

It appears that it will be more challenging than expected to recapitulate human TBI-related tau pathology using transgenic mouse models. Nonetheless, significant technical advances have been made and there are several feasible paths forward which if successful, will allow development a pharmacodynamically useful preclinical model and non-invasive blood or CSF biomarker for TBI-related tauopathy.

REFERENCES:

1. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *Journal of neuropathology and experimental neurology*. 2009 Jul;68(7):709-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19535999
2. Corsellis JAN, Brunton CJ, Freeman-Browne D. The aftermath of boxing. *Psychological medicine*. 1973;3:270-303.
3. Jordan BD. Chronic traumatic brain injury associated with boxing. *Seminars in neurology*. 2000;20(2):179-85. <http://www.ncbi.nlm.nih.gov/pubmed/10946737>.
4. Omalu BI, DeKosky ST, Hamilton RL, et al. Chronic traumatic encephalopathy in a national football league player: part II. *Neurosurgery*. 2006 Nov;59(5):1086-92; discussion 92-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17143242
5. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. *Neurosurgery*. 2005 Jul;57(1):128-34; discussion -34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15987548
6. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. *Acta neuropathologica*. 1999 Aug;98(2):171-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10442557
7. Costanza A, Weber K, Gandy S, et al. Review: Contact sport-related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates. *Neuropathology and applied neurobiology*. 2011 Oct;37(6):570-84. <http://www.ncbi.nlm.nih.gov/pubmed/21696410>.
8. Aotsuka A, Kojima S, Furumoto H, Hattori T, Hirayama K. [Punch drunk syndrome due to repeated karate kicks and punches]. *Rinsho shinkeigaku = Clinical neurology*. 1990 Nov;30(11):1243-6. <http://www.ncbi.nlm.nih.gov/pubmed/2085930>.
9. Critchley M. Medical aspects of boxing, particularly from a neurological standpoint. *British medical journal*. 1957 Feb 16;1(5015):357-62. <http://www.ncbi.nlm.nih.gov/pubmed/13396257>.
10. Jordan BD. Neurologic aspects of boxing. *Archives of neurology*. 1987 Apr;44(4):453-9. <http://www.ncbi.nlm.nih.gov/pubmed/3827699>.
11. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. *Journal of neurology, neurosurgery, and psychiatry*. 1990 May;53(5):373-8. <http://www.ncbi.nlm.nih.gov/pubmed/2191084>.
12. Martland HS. Punch drunk. *JAMA : the journal of the American Medical Association*. 1928;91:1103-7.
13. Omalu B, Hammers JL, Bailes J, et al. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. *Neurosurgical focus*. 2011 Nov;31(5):E3. <http://www.ncbi.nlm.nih.gov/pubmed/22044102>.
14. Perl D. Plenary Lecture: Chronic Traumatic Encephalopathy (CTE). Federal Interagency Conference on Traumatic Brain Injury; 6/15/2011; Washington DC2011.
15. Roberts GW, Whitwell HL, Acland PR, Bruton CJ. Dementia in a punch-drunk wife. *Lancet*. 1990;335(8694):918-9. <http://www.ncbi.nlm.nih.gov/pubmed/1970008>.
16. Hof PR, Knabe R, Bovier P, Bouras C. Neuropathological observations in a case of autism presenting with self-injury behavior. *Acta neuropathologica*. 1991;82(4):321-6. <http://www.ncbi.nlm.nih.gov/pubmed/1759563>.
17. Williams DJ, Tannenberg AE. Dementia pugilistica in an alcoholic achondroplastic dwarf. *Pathology*. 1996 Jan;28(1):102-4. <http://www.ncbi.nlm.nih.gov/pubmed/8714284>.
18. Schmidt ML, Zhukareva V, Newell KL, Lee VM, Trojanowski JQ. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. *Acta Neuropathol (Berl)*. 2001;101(5):518-24. <http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11484824>.
19. Geddes JF, Vowles GH, Robinson SF, Sutcliffe JC. Neurofibrillary tangles, but not Alzheimer-type pathology, in a young boxer. *Neuropathology and applied neurobiology*. 1996 Feb;22(1):12-6. <http://www.ncbi.nlm.nih.gov/pubmed/8866777>.
20. Tokuda T, Ikeda S, Yanagisawa N, Ihara Y, Glenner GG. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. *Acta neuropathologica*. 1991;82(4):280-5. <http://www.ncbi.nlm.nih.gov/pubmed/1759560>.
21. Johnson VE, Stewart W, Smith DH. Widespread Tau and Amyloid-Beta Pathology Many Years After a Single Traumatic Brain Injury in Humans. *Brain Pathol*. 2011 Jun 29. <http://www.ncbi.nlm.nih.gov/pubmed/21714827>.
22. Uryu K, Chen XH, Martinez D, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. *Experimental neurology*. 2007 Dec;208(2):185-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17826768
23. Ikonomic MD, Uryu K, Abrahamson EE, et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. *Experimental neurology*. 2004 Nov;190(1):192-203. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15473992

24. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. *Nature reviews Neuroscience*. 2010 Mar;11(3):155-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20029438
25. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. *The Journal of biological chemistry*. 2009 May 8;284(19):12845-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19282288
26. Kfoury N, Holmes B, Jiang H, Holtzman D, Diamond MI. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. 2012 *Submitted*.
27. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. *Nature cell biology*. 2009 Jul;11(7):909-13. <http://www.ncbi.nlm.nih.gov/pubmed/19503072>.
28. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. *Trends in neurosciences*. 2010 Jul;33(7):317-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20493564
29. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. *Neuron*. 2009 Dec 24;64(6):783-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20064386
30. Polydoro, Calignon D, Suárez-Calvet, et al. Propagation of tau pathology in a model of early Alzheimer's disease Society for Neuroscience; Washington DC2011.
31. Tran HT, Laferla FM, Holtzman DM, Brody DL. Controlled Cortical Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-Axonal Amyloid-beta Accumulation and Independently Accelerates the Development of Tau Abnormalities. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011 Jun 29;31(26):9513-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21715616
32. Tran HT, Sanchez L, Esparza TJ, Brody DL. Distinct Temporal and Anatomical Distributions of Amyloid-beta and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice. *PloS one*. 2011;6(9):e25475. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21980472
33. Tran HT, Sanchez L, Brody DL. Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury-Induced Tauopathy in Transgenic Mice. *Journal of neuropathology and experimental neurology*. 2012 Feb;71(2):116-29. <http://www.ncbi.nlm.nih.gov/pubmed/22249463>.
34. Lee MJ, Lee JH, Rubinshtein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. *Progress in neurobiology*. 2013 Jun;105:49-59. <http://www.ncbi.nlm.nih.gov/pubmed/23528736>.
35. Mouzon BC, Bachmeier C, Ferro A, et al. Chronic neuropathological and neurobehavioral changes in a repetitive mTBI model. *Annals of neurology*. 2013 Nov 16. <http://www.ncbi.nlm.nih.gov/pubmed/24243523>.

Appendices: None.